


Supplemental Materials

Impact of different classes of immune-modulating treatments on B- and T-cell related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study

Supplemental figure 1. Levels for interferon-gamma release assay by type of treatment (csDMARD [n=4] vs bDMARD [n=17]) and visit.



bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug.